retatrutide type 2 diabetes trial results 2024 2025 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Phase 2 trial results demonstrate

The data and biosamples collected or generated by QBB will be made available to researchers employed within or otherwise contractually bound to public and private institutions that conduct scientific research and that meet the requirements detailed in the Qatar Biobank Research Access policy

DSIP exhibits an unusual property among neuropeptides in that it appears relatively stable in plasma despite its small size, a characteristic researchers have attributed to possible circulating binding proteins

Spirou, D., Raman, J

BPC-157 has never been tested in humans for GERD, acid reflux, or any other medical condition

There is currently no data to support this